

PHARMACEUTICAL 2017



Lipocine Inc. Rank 74 of 292







PHARMACEUTICAL 2017

Lipocine Inc. Rank 74 of 292



The relative strengths and weaknesses of Lipocine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lipocine Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 126% points. The greatest weakness of Lipocine Inc. is the variable Net Income, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 180%, being 177% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	27,209
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,326
Liabilities, Non-Current	0
Other Assets	31
Other Compr. Net Income	24
Other Expenses	729
Other Liabilities	0
Other Net Income	216
Other Revenues	0
Property and Equipment	103
Research and Development	8,076
Selling, General and Administrative Expense	10,382

Output Variable	Value in 1000 USD
Assets	27,343
Liabilities	1,326
Expenses	19,188
Revenues	0
Stockholders Equity	26,017
Net Income	-18,972
Comprehensive Net Income	-18,959
Economic Capital Ratio	180%

